Forma farmacéutica: Solución oral
Concentración: Aripiprazol 1 mg/mL
Indicación terapéutica: Tratamiento de mantenimiento de la esquizofrenia en adultos previamente estabilizados con aripiprazol oral
Estado de aprobación regulatoria: Medicamento con receta (Rx), sujeto a la aprobación de la autoridad reguladora nacional

Otra información

Descripción adicional:

Abilify Maintena is an antipsychotic medicine containing aripiprazole as its active substance, used as maintenance treatment for schizophrenia in adults already stabilized on oral aripiprazole. While its precise mechanism is unclear, it binds brain receptors for the neurotransmitters dopamine and serotonin, both believed to play a role in schizophrenia; by engaging these receptors, aripiprazole is thought to help normalize brain activity, easing psychotic symptoms and helping prevent their return. Schizophrenia presents with symptoms including disorganized thinking and speech, hallucinations, suspiciousness, and delusions.